Malaria vaccine developments

Lancet

Volumn 363, Issue 9403, 2004, Pages 150-156

  Moorthy, Vasee S ^a,b,d   Good, Michael F ^c   Hill, Adrian V S ^b  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d Malaria Vaccine Initiative   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE;

BLOOD; CLINICAL TRIAL; DEVELOPMENTAL STAGE; DRUG EFFICACY; ERYTHROCYTE; GENE SEQUENCE; GENOME; HISTORY OF MEDICINE; HUMAN; IMMUNITY; LIFE CYCLE; MALARIA; NONHUMAN; PLASMODIUM FALCIPARUM; PREDICTION; PRIORITY JOURNAL; REVIEW; SEXUALITY; SPECIES INVASION; VACCINATION;

EID: 0346056892     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)15267-1     Document Type: Review

References (81)

1. Russell P.F. Man's mastery of malaria. 1955;Oxford University Press, London.
2. Malaria fact sheet no 94. 1996;World Health Organization, Geneva.
3. Malaria - a global crisis. 2000;World Health Organization, Geneva.
4. Shanks G.D., Biomndo K., Hay S.I., Snow R.W. Changing patterns of clinical malaria since 1965 among a tea estate population located in the Kenyan highlands. Trans R Soc Trop Med Hyg. 94:2000;253-255.
5. le Sueur D., Sharp B.L., Gouws E., Ngxongo S. Malaria in South Africa. S Afr Med J. 86:1996;936-939.
6. Greenwood B., Mutabingwa T. Malaria in 2002. Nature. 415:2002;670-672.
7. Hemingway J., Field L., Vontas J. An overview of insecticide resistance. Science. 298:2002;96-97.
8. Guerin P.J., Olliaro P., Nosten F., et al. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis. 2:2002;564-573.
9. Martens P., Hall L. Malaria on the move: human population movement and malaria transmission. Emerg Infect Dis. 6:2000;103-109.
10. Muentener P., Schlagenhauf P., Steffen R. Imported malaria (1985-95): trends and perspectives. Bull World Health Organ. 77:1999;560-566.
11. Snow R.W., Trape J.F., Marsh K. The past, present and future of childhood malaria mortality in Africa. Trends Parasitol. 17:2001;593-597.
12. Sachs J.D. A new global effort to control malaria. Science. 298:2002;122-142.
13. Beverley P.C. Immunology of vaccination. Br Med Bull. 62:2002;15-28.
14. Gardner M.J., Hall N., Fung E., et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature. 419:2002;498-511.
15. Clyde D.F., Most H., McCarthy V.C., Vanderberg J.P. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci. 266:1973;169-177.
16. Hoffman S.L., Goh L.M., Luke T.C., et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis. 185:2002;1155-1164.
17. Kwiatkowski D., Marsh K. Vaccine series: development of a malaria vaccine. Lancet. 350:1997;1696-1701.
18. Cochrane A.H., Nussenzweig R.S., Nardin E.H. Immunization against sporozoites. Kreier J.P. Malaria. 1980;New York Academic Press, New York.
19. Patarroyo G., Franco L., Amador R., et al. Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1-14 years. Vaccine. 10:1992;175-178.
20. Alonso P.L., Smith T., Schellenberg J.R., et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet. 344:1994;1175-1781.
21. D'Alessandro U., Leach A., Drakeley C.J., et al. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet. 346:1995;462-467.
22. Nosten F., Luxemburger C., Kyle D.E., et al. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet. 348:1996;701-707.
23. Acosta C.J., Galindo C.M., Schellenberg D., et al. Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania. Trop Med Int Health. 4:1999;368-376.
24. Moorthy V., Hill A.V. Malaria vaccines. Br Med Bull. 62:2002;59-72.
25. Rosenberg R., Wirtz R.A., Schneider I., Burge R. An estimation of the number of malaria sporozoites ejected by a feeding mosquito. Trans R Soc Trop Med Hyg. 84:1990;209-212.
26. Ponnudurai T., Lensen A.H., van Gemert G.J., Bolmer M.G., Meuwissen J.H. Feeding behaviour and sporozoite ejection by infected Anopheles stephensi. Trans R Soc Trop Med Hyg. 85:1991;175-180.
27. Mota M.M., Pradel G., Vanderberg J.P., et al. Migration of Plasmodium sporozoites through cells before infection. Science. 291:2001;141-144.
28. Mota M.M., Hafalla J.C., Rodriguez A. Migration through host cells activates Plasmodium sporozoites for infection. Nat Med. 8:2002;1318-1322.
29. Crosnier J., Jungers P., Courouce A.M., et al. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, Medical staff. Lancet. 1:1981;455-459.
30. Ulmer J.B., Donnelly J.J., Parker S.E., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 259:1993;1745-1749.
31. Li S., Rodrigues M., Rodriguez D., et al. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci USA. 90:1993;5214-5218.
32. Wang R., Doolan D.L., Le T.P., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 282:1998;476-480.
33. Schneider J., Gilbert S.C., Blanchard T.J., et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med. 4:1998;397-402.
34. Gurunathan S., Klinman D.M., Seder R.A. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol. 18:2000;927-974.
35. Miyahira Y., Garcia-Sastre A., Rodriguez D., et al. Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8(+) responses in mice. Proc Natl Acad Sci USA. 95:1998;3954-3959.
36. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci USA. 93:1996;11349-11353.
37. Kabilan L., Troye-Blomberg M., Andersson G., et al. Number of cells from Plasmodium falciparum-immune donors that produce gamma interferon in vitro in response to Pf155/RESA, a malaria vaccine candidate antigen. Infect Immun. 58:1990;2989-2994.
38. Lalvani A., Brookes R., Hambleton S., Britton W.J., Hill A.V., McMichael A.J. Rapid effector function in CD8+ memory T cells. J Exp Med. 186:1997;859-865.
39. Altman J.D., Moss P.A., Goulder P.J., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:1996;94-96.
40. McGregor I.A. Mechanisms of acquired immunity and epidemiological patterns of antibody responses in malaria in man. Bull World Health Organ. 50:1974;259-266.
41. Cohen S., McGregor I.A., Carrington S. Gamma globulin and acquired immunity to malaria. Nature. 192:1961;733-737.
42. Marsh K., Howard R.J. Antigens induced on erythrocytes by P falciparum: expression of diverse and conserved determinants. Science. 231:1986;150-153.
43. Bouharoun-Tayoun H., Attanath P., Sabchareon A., Chongsuphajaisiddhi T., Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med. 172:1990;1633-1641.
44. Florens L., Washburn M.P., Raine J.D., et al. A proteomic view of the Plasmodium falciparum life cycle. Nature. 419:2002;520-526.
45. Doolan D.L., Hoffman S.L. DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation. Int J Parasitol. 31:2001;753-762.
46. Stoute J.A., Slaoui M., Heppner D.G., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med. 336:1997;86-91.
47. Potocnjak P., Yoshida N., Nussenzweig R.S., Nussenzweig V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J Exp Med. 151:1980;1504-1513.
48. Nardin E.H., Nussenzweig V., Nussenzweig R.S., et al. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J Exp Med. 156:1982;20-30.
49. Kester K.E., McKinney D.A., Tornieporth N., et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis. 183:2001;640-647.
50. Church L.W., Le T.P., Bryan J.P., et al. Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis. 175:1997;915-920.
51. Ballou W.R., Hoffman S.L., Sherwood J.A., et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet. 1:1987;1277-1281.
52. Herrington D.A., Clyde D.F., Losonsky G., et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature. 328:1987;257-259.
53. Sherwood J.A., Oster C.N., Adoyo-Adoyo M., et al. Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine: boosting of antibody response in a population with prior natural exposure to malaria. Trans R Soc Trop Med Hyg. 85:1991;336-340.
54. Vreden S.G., Verhave J.P., Oettinger T., Sauerwein R.W., Meuwissen J.H. Phase I clinical trial of a recombinant malaria vaccine consisting of the circumsporozoite repeat region of Plasmodium falciparum coupled to hepatitis B surface antigen. Am J Trop Med Hyg. 45:1991;533-538.
55. Herrington D.A., Losonsky G.A., Smith G., et al. Safety and immunogenicity in volunteers of a recombinant Plasmodium falciparum circumsporozoite protein malaria vaccine produced in Lepidopteran cells. Vaccine. 10:1992;841-846.
56. Brown A.E., Singharaj P., Webster H.K., et al. Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers. Vaccine. 12:1994;102-108.
57. Gonzalez C., Hone D., Noriega F.R., et al. Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J Infect Dis. 169:1994;927-931.
58. Hoffman S.L., Edelman R., Bryan J.P., et al. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant. Am J Trop Med Hyg. 51:1994;603-612.
59. Bojang K.A., Milligan P.J., Pinder M., et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet. 358:2001;1927-1934.
60. Alloueche A., Milligan P., Conway D.J., et al. Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific. Am J Trop Med Hyg. 68:2003;97-101.
61. Birkett A., Lyons K., Schmidt A., et al. A modified hepatitis b virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts. Infect Immun. 70:2002;6860-6870.
62. Schneider J., Gilbert S.C., Hannan C.M., et al. Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol Rev. 170:1999;29-38.
63. Moorthy V.S., McConkey S., Roberts M., et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P falciparum malaria in non-immune volunteers. Vaccine. 21:2003;2004-2011.
64. Moorthy VS, Pinder M, Reece WHH, et al. Safety and immunogenicity of DNA/modified vaccinia virus Ankara malaria vaccination in African adults. J Infect Dis (in press).
65. McConkey S., Reece W.H.H., Moorthy V.S., et al. Enhanced T-cell immunogenicity in humans of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara. Nat Med. 9:2003;729-735.
66. Richie T.L., Wang R., Charoenvit Y., et al. Safety, immunogenicity and efficacy of MuStDO5, a five gene sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with human GM-CSF DNA (conference abstract). Am J Trop Med Hyg. 65:(suppl):2001;230.
67. Rogers W.O., Weiss W.R., Kumar A., et al. Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen. Infect Immun. 70:2002;4329-4335.
68. Wang R., Epstein J., Baraceros F.M., et al. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci USA. 98:2001;10817-10822.
69. Nardin E.H., Oliveira G.A., Calvo-Calle J.M., et al. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. J Infect Dis. 182:2000;1486-1496.
70. Nardin E.H., Calvo-Calle J.M., Oliveira G.A., et al. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types. J Immunol. 166:2001;481-489.
71. Lopez J.A., Weilenman C., Audran R., et al. A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans: implications for vaccination strategies. Eur J Immunol. 31:2001;1989-1998.
72. Holder A.A., Guevara Patino J.A., Uthaipibull C., et al. Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. Parassitologia. 41:1999;409-414.
73. Genton B., Betuela I., Felger I., et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis. 185:2002;820-827.
74. Ockenhouse C.F., Sun P.F., Lanar D.E., et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis. 177:1998;1664-1673.
75. Oeuvray C., Theisen M., Rogier C., Trape J.F., Jepsen S., Druilhe P. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect Immun. 68:2000;2617-2620.
76. Oeuvray C., Bouharoun-Tayoun H., Gras-Masse H., et al. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood. 84:1994;1594-1602.
77. Makobongo M.O., Riding G., Xu H., et al. The purine salvage enzyme hypoxanthine guanine xanthine phosphoribosyl transferase is a major target antigen for cell-mediated immunity to malaria. Proc Natl Acad Sci USA. 100:2003;2628-2633.
78. Pombo D.J., Lawrence G., Hirunpetcharat C., et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet. 360:2002;610-617.
79. Cheng Q., Lawrence G., Reed C., et al. Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines. Am J Trop Med Hyg. 57:1997;495-500.
80. Schofield L., Hewitt M.C., Evans K., Siomos M.A., Seeberger P.H. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature. 418:2002;785-789.
81. Molano A., Park S.H., Chiu Y.H., Nosseir S., Bendelac A., Tsuji M. Cutting edge: the IgG response to the circumsporozoite protein is MHC class II-dependent and CD1d-independent: exploring the role of GPIs in NK T cell activation and antimalarial responses. J Immunol. 164:2000;5005-5009.